- Title
- FRI-158-Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
- Creators
- Maria ButiNamiki IzumiYoung-Suk LimHarry JanssenJia-Horng KaoAdrian Streinu-CercelElena NurmukhametovaXiaoli MaTabak FehmiMaciej JablkowskiVithika SuriJohn F. FlahertyAudrey LauAnuj GaggarShuyuan MoAbhijit ChaudhuriScott FungWan-Long ChuangEdward Gane
- Publication Details
- Journal of hepatology, v 70(1), pp e457-e458
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000463481701485
- Other Identifier
- 991019167691004721
Journal article
FRI-158-Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment
Journal of hepatology, v 70(1), pp e457-e458
Apr 2019
Metrics
10 Record Views
Details
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology